Healthcare Sector

BMY

Market Tracker

$57.67
+0.05
(+0.09%)
10:59 am
Next Earnings: (est.) 07/27/23 12:00 am
  • BMY (Selected)

    Bristol-Myers Squibb Company

BMY Support / Resistance Levels

Loading Data..
WhaleStream

15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.

BMY Most Active Options Strike Prices Whale BUY Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.

BMY Most Active Options Strike Prices Whale SALES Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.

BMY Dark Pool and Public Equity Key Price Levels

Loading Data..

Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.

BMY Open Interest Trend

Loading Data..

Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.

BMY Largest 1-Day Open Interest Movements

Expires Type Strike OI Change Percent
07/02/2026 CALL $60.00 7,981 +7,283 +1,043.41%
07/10/2026 CALL $60.00 3,564 +3,214 +918.29%
07/10/2026 PUT $55.00 2,528 +2,381 +1,619.73%
07/02/2026 CALL $61.00 1,076 +760 +240.51%
07/17/2026 CALL $61.00 726 +678 +1,412.50%
01/21/2028 CALL $80.00 599 +551 +1,147.92%
07/17/2026 CALL $55.00 6,485 -37 -0.57%
12/18/2026 PUT $57.50 1,993 -37 -1.82%
07/02/2026 CALL $57.00 1,040 -52 -4.76%
09/18/2026 CALL $55.00 7,494 -54 -0.72%
12/18/2026 CALL $57.50 2,858 -54 -1.85%
07/17/2026 PUT $52.50 4,934 -977 -16.53%

Contracts with largest changes in open interest from the previous trading day to the current/most recent.

BMY Major Holders

Name Pct Held Shares Total
Vanguard Total Stock Market Index Fund 3.07% 64.63M 4.03B
Vanguard 500 Index Fund 2.34% 49.15M 3.06B
Fidelity 500 Index Fund 1.11% 23.31M 1.45B
SPDR S&P 500 ETF Trust 1.09% 23.02M 1.43B
iShares Core S&P 500 ETF 0.90% 18.98M 1.18B
Vanguard Index-Value Index Fund 0.87% 18.37M 1.14B
JP Morgan Equity Income Fund 0.82% 17.35M 1.08B
Select Sector SPDR Fund-Health Care 0.82% 17.27M 1.08B
American Mutual Fund Inc 0.78% 16.49M 1.03B
Vanguard Institutional Index Fund-Institutional Index Fund 0.71% 14.9M 927.91M

BMY News

  • Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

    06/26 11:30 am

    The Motley Fool

    Read more
  • Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda

    06/23 08:00 am

    GlobeNewswire Inc.

    Read more
  • Should You Buy Moderna Before Aug. 5?

    06/22 06:10 pm

    The Motley Fool

    Read more
  • Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight

    06/22 01:00 pm

    GlobeNewswire Inc.

    Read more
  • Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook

    06/18 07:09 pm

    The Motley Fool

    Read more
  • 3 Dividend Stocks to Hold for the Long Haul

    06/16 06:15 am

    The Motley Fool

    Read more
  • How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take.

    06/13 06:15 pm

    The Motley Fool

    Read more
  • Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue.

    06/11 02:02 pm

    The Motley Fool

    Read more
  • Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med

    06/11 01:12 pm

    Benzinga

    Read more
  • Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery

    06/10 02:35 am

    GlobeNewswire Inc.

    Read more
  • Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer?

    06/04 02:30 am

    The Motley Fool

    Read more
  • Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?

    06/02 05:12 pm

    The Motley Fool

    Read more
  • Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks

    06/01 11:15 pm

    The Motley Fool

    Read more
  • CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking

    06/01 12:30 pm

    The Motley Fool

    Read more
  • CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?

    05/31 12:11 pm

    The Motley Fool

    Read more
  • Globale Daten der ROSETTA Lung-02-Studie: Ermutigende Wirksamkeit für BioNTechs und Bristol Myers Squibbs bispezifischen PD-L1xVEGF-A-Immunmodulator-Kandidat Pumitamig bei nicht-kleinzelligem Lungenkrebs

    05/30 02:15 pm

    GlobeNewswire Inc.

    Read more
  • Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

    05/30 02:15 pm

    GlobeNewswire Inc.

    Read more
  • BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

    05/22 05:00 am

    GlobeNewswire Inc.

    Read more
  • BioNTech präsentiert auf der ASCO-Jahrestagung 2026 Fortschritte aus Pipelineprogrammen in der späten klinischen Entwicklung

    05/22 05:00 am

    GlobeNewswire Inc.

    Read more
  • The Most Undervalued Healthcare Stock in the S&P 500 Right Now

    05/21 07:05 am

    The Motley Fool

    Read more
  • Anthropic And OpenAI--Building Different Competitive Advantages

    05/20 02:18 pm

    Benzinga

    Read more
  • Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery

    05/20 01:09 pm

    Benzinga

    Read more
  • Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts

    05/14 02:23 pm

    Benzinga

    Read more
  • Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight

    05/13 01:00 pm

    GlobeNewswire Inc.

    Read more
  • AstraZeneca's Rare Disease Drug Shows Reduced Dependence On Calcium Supplements

    05/12 10:03 am

    Benzinga

    Read more
  • Wall Street's Cardiac Bet: Where Diagnostics Meet the Money

    05/12 08:30 am

    Benzinga

    Read more
  • Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors.

    05/11 09:15 pm

    The Motley Fool

    Read more
  • Global Personalized Medicine to Transform Modern Healthcare and Cross USD 1 Trillion by 2034 | DelveInsight

    05/11 01:00 pm

    GlobeNewswire Inc.

    Read more
  • Why Bristol Myers Squibb Stock Rocked the Market Today

    04/30 04:17 pm

    The Motley Fool

    Read more
  • Why Is Bristol-Myers Squibb Stock Trading Higher On Thursday?

    04/30 02:12 pm

    Benzinga

    Read more
  • Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape

    04/28 01:00 pm

    GlobeNewswire Inc.

    Read more
  • Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash Deal

    04/27 05:34 pm

    The Motley Fool

    Read more
  • AI Disruption in Lung Cancer Therapeutics Set to Transform Treatment Paradigms as Billion-Dollar Investments Drive Innovation

    04/27 01:36 pm

    GlobeNewswire Inc.

    Read more
  • Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight

    04/27 01:00 pm

    GlobeNewswire Inc.

    Read more
  • 3 Biotech Stocks That Could Benefit from the Patent Cliff

    04/27 11:29 am

    Investing.com

    Read more
  • Vulvar Cancer Market Global and Regional Analysis Report 2025-2035, Profiles of Merck & Co., Bristol Myers Squibb, and AstraZeneca

    04/22 05:59 am

    GlobeNewswire Inc.

    Read more
  • Follicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsight

    04/21 01:00 pm

    GlobeNewswire Inc.

    Read more
  • Targeted Alpha Therapy Market Landscape Report 2026-2030: Clinical Trials Insights on 30 Drugs - Size, Regulatory Approvals, Proprietary Technologies, Therapeutic Applications

    04/21 04:27 am

    GlobeNewswire Inc.

    Read more
  • Oncolytic Virus Immunotherapy Market Landscape Report 2026: A $5 Opportunity by 2031 - Technology Platforms, Approved Therapy Dosage, Price & Clinical Trials Insights

    04/21 04:14 am

    GlobeNewswire Inc.

    Read more
  • Alpha Thalassemia (US, EU4, UK, and Japan) Market Insights, Epidemiology, and Forecasts 2022-2025 & 2025-2036

    04/13 04:47 am

    GlobeNewswire Inc.

    Read more
  • Which Dividend Pharma Stock Should a Value Investor Choose Today?

    04/12 08:28 pm

    The Motley Fool

    Read more
  • 2 Recession Resistant Dividend Stocks to Buy Now While They're Still Cheap

    04/10 06:30 am

    The Motley Fool

    Read more
  • 7MM Systemic Lupus Erythematosus and Lupus Nephritis Drug Market Analysis & Forecast 2024-2034: Future SLE and LN Players Competition, High Unmet Need for Steroid-sparing Treatments

    04/10 04:59 am

    GlobeNewswire Inc.

    Read more
  • Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours

    04/09 07:00 am

    GlobeNewswire Inc.

    Read more
  • Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight

    04/08 01:00 pm

    GlobeNewswire Inc.

    Read more
  • Trump Imposes 100% Drug Tariffs: 5 Pharma Stocks That Won’t Pay a Dime

    04/06 01:20 pm

    Investing.com

    Read more
  • Esophageal Cancer Market to Grow from $1.65 Billion in 2026 to $2.37 Billion by 2030: Pfizer, Roche, Merck & Co. Dominate

    03/30 05:00 am

    GlobeNewswire Inc.

    Read more
  • What Is Considered a Good Stock Dividend? 2 Healthcare Stocks Fit the Bill.

    03/24 07:06 am

    The Motley Fool

    Read more
  • Should You Buy Bristol Myers Squibb Stock for Its 4.4%-Yielding Dividend?

    03/23 04:30 pm

    The Motley Fool

    Read more
👀

Follow the Whales in real-time.

🎁

Take 50% OFF With Code: